These results are indicative of a model in which redundancy in granzymes facilitates killing against leukemias/lymphomas with low Fas expression whereas redundancy between GZMB and FasL facilitates killing of solid tumor targets with high Fas expression. The gene discussed is GZMB; the disease is lymphoma.